| Outcome
|
Findings in words
|
Findings in numbers
|
Quality of evidence
|
| Global state
|
Clinical improvement
Follow-up: average 19 weeks |
Trifluoperazine increases the chance of being 'improved' when compared to placebo. Data are based on low quality evidence.
|
RR 4.61 (1.54 to 13.84) |
Low
|
Relapse or worsening
Follow-up: average 5 months |
Trifluoperazine reduces the risk of relapse when compared with placebo. Data are based on low quality evidence.
|
RR 0.34 (0.23 to 0.49) |
Low
|
| Mental state
|
Experiencing 'intensified symptoms'
Follow-up: average 16 weeks |
At present it is not possible to be confident about the difference between trifluoperazine and placebo for this outcome and data supporting this finding are very limited.
|
RR 1.05 (0.54 to 2.05) |
Very low
|
| Leaving the study early
|
- Because of any reason
Follow-up: average 5 months |
Trifluoperazine may reduce loss to follow-up, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited.
|
RR 0.67 (0.38 to 1.19) |
Very low
|
- Because of severe adverse effects
Follow-up: average 2 months |
It is not possible to be confident about the difference between trifluoperazine and placebo. Data supporting this finding are very limited.
|
RR 1.31 (0.22 to 7.8) |
Very low
|
| Behavior
|
Any clinically significant agitation or distress
Follow-up: 4 months |
There was no clear differences between trifluoperazine and placebo for this outcome. Data supporting this finding are very limited.
|
RR 2.0 (0.19 to 20.72) |
Very low
|
| Economic outcomes
|
|
No included randomized study reported on economic outcomes. |
|
|